SUPPORTING INFORMATION

Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P

Nathan P. Lavey,[†,‡,§] Jesse A. Coker,[†,‡,§] Eliza A. Ruben,[§,⊥] and Adam S. Duerfeldt*[,‡,§]

[‡]*Institute for Natural Products Applications and Research Technologies and* [§]*Department of Chemistry & Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma 73019, United States*

[⊥]*Protein Production Core, University of Oklahoma COBRE in Structural Biology, Norman, OK, 73019, United States*

[†]Authors contributed equally

*Corresponding author

TABLE OF CONTENTS

A.



B.



Figure S1. (A) Structure of enopeptin A. (B) Structure of ACP5



Figure S2. B-score representation of the initial natural product screen against *Ec*ClpP. Red-dashed line indicates three standard deviations from the mean general sample population. A = enopeptin A, B = ACP5, C-J = "hits" according to ΔRFU data, (1) = sclerotiamide.



Figure S3. SDS-PAGE analysis of ClpP homologue dependent degradation of unlabeled β-casein by ACP5.

A.



B.



Figure S4. Dose dependent *Ec*ClpP activation by ADEP1. (A) substrate = Abz-DFAPKMALVPY^{NO2} (B) substrate = FITC-β-casein.